Characteristics and outcomes of chronic pulmonary aspergillosis: A retrospective analysis of a tertiary hospital registry

Clinical Respiratory Journal

Volumn 9, Issue 1, 2015, Pages 65-73

  Camara, Boubou ^a,b   Reymond, Emilie ^a,b   Saint Raymond, Christel ^a,b   Roth, Hubert ^a,b,e,f   Brenier Pinchart, Marie Pierre ^a,b   Pinel, Claudine ^a,b   Cadranel, Jacques ^c,d   Ferretti, Gilbert ^a,b   Pelloux, Hervé ^a,b   Pison, Christophe ^a,b,f   Camara, B ^d   Quetant, S ^d   Lebeau, B ^d   Thiebaut, A Bertrand ^d   Saint, C Raymond ^d   Maubon, D ^d   Bosseray, A ^d   Hamidfar, R ^d   Pinel, C ^d   Pelloux, H ^d   Brenier Pinchart, M P ^d   Mallaret, M R ^d   Plantaz, D ^d   Goutier, S ^d   Cornet, M ^d   Epaulard, O ^d   Reymond, E ^d   Ferretti, G ^d   more..

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c HÔPITAL TENON   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Univ Lyon   (France)

^f Inserm1055   (France)

Author keywords

Aspergillus; BMI; Chronic pulmonary aspergillosis; COPD

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; PRECIPITIN; VORICONAZOLE; ANTIFUNGAL AGENT;

AGED; AJELLOMYCES CAPSULATUS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC PNEUMONITIS; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; ASPERGILLOMA; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; BODY MASS; BRONCHIECTASIS; CHARLSON COMORBIDITY INDEX; CHRONIC CAVITARY PULMONARY ASPERGILLOSIS; CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS; CHRONIC PULMONARY ASPERGILLOSIS; CLINICAL ARTICLE; COCCIDIOIDES IMMITIS; CONTROLLED STUDY; EMPHYSEMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG ASPERGILLOSIS; MALE; MYCETOMA; OTOMYCOSIS; PATIENT HISTORY OF RADIOTHERAPY; PLEURA EFFUSION; PLEURA THICKENING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; CHRONIC DISEASE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; REGISTER; TERTIARY CARE CENTER;

AGED; ANTIFUNGAL AGENTS; BODY MASS INDEX; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84923208957     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12105     Document Type: Article

References (30)

1. Walsh TJ, Anaissie EJ, Denning DW, etal. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3): 327-360.
2. Segal BH. Aspergillosis. N Engl J Med. 2009;360(18): 1870-1884.
3. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003;37(Suppl 3): S265-280.
4. Garnaud C, Brenier-Pinchart MP, Thiebaut-Bertrand A, etal. Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital. J Infect. 2012;65(6): 559-567.
5. Fourneret-Vivier A, Lebeau B, Mallaret MR, etal. Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002). J Hosp Infect. 2006;62(1): 22-28.
6. Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51(12): 1383-1391.
7. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011;37(4): 865-872.
8. Ascioglu S, Rex JH, de Pauw B, etal. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1): 7-14.
9. De Pauw B, Walsh TJ, Donnelly JP, etal. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12): 1813-1821.
10. Stevens DA, Melikian GL. Aspergillosis in the 'nonimmunocompromised' host. Immunol Invest. 2011;40(7-8): 751-766.
11. Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol. 1997;28(6): 650-656.
12. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol. 2005;43(Suppl 1): S207-238.
13. Hope WW, Kruhlak MJ, Lyman CA, etal. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007;195(3): 455-466.
14. Yang L, Zhou M, Smith M, Yang G, Peto R, Wang J, Boreham J, Hu Y, Chen Z. Body mass index and chronic obstructive pulmonary disease-related mortality: a nationally representative prospective study of 220, 000 men in China. Int J Epidemiol. 2010;39(4): 1027-1036.
15. Ringbaek TJ, Viskum K, Lange P. BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy. Chron Respir Dis. 2004;1(2): 71-78.
16. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1): 1791-1797.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5): 373-383.
18. Barberan J, Sanz F, Hernandez JL, etal. Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. J Infect. 2012;65(5): 447-452.
19. Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Koh WJ. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14(6): e479-482.
20. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23(3 Pt 2): 607-614.
21. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, Dauriat G, Mangiapan G, Rabbat A, Cadranel J. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007;131(5): 1435-1441.
22. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006;52(5): e133-137.
23. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119(6): 527.e17-52724.
24. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, Kakeya H, Niki Y, Miyazaki Y. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61(5): 410-418.
25. Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I, Carandell E, Agusti M, Ayuso P, Estela A, Torres A. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31(6): 1274-1284.
26. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8): 775-789.
27. White DA. Drug-induced pulmonary infection. Clin Chest Med. 2004;25(1): 179-187.
28. Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med. 2005;26(1): 11-17.
29. Cadranel J, Philippe B, Hennequin C, etal. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012;31(11): 3231-3239.
30. Pison CM, Cano NJ, Cherion C, etal. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax. 2011;66(11): 953-960.